The main focus of our research is the use of Cancer Nanotechnology for Precision Medicine in order to tackle crucial medical problems involved in the development of novel and highly effective diagnostic and therapy platforms for cancer. Cancer has become the chief innovator of ground-breaking platforms that can be used for Precision Medicine. Determining the response profile of a tumor, detecting key players in tumor progression, and trying to disable those drivers with targeted therapies and engineered materials so as to “smash” the brakes on malignant and metastatic cells to control proliferation is the modus operandi of our research. Cancer Nanotechnology is becoming a burgeoning field, and we are sure that will aim to bring reality to the Precision Medicine initiative.

    It is now crucial to empower the potential of Nanomedicine to differentially combat cancer using smart and targeted platforms that mediate highly selective therapies within the tumor microenvironment. The lack of standardized means to treat and profile the tumor microenvironment calls for a paradigm shift in the way we view and treat cancer.

 

In this paradigm, our research focus on tackling real biomedical problems and developing smart materials to beat cancer.

​

     Conde NanoLab is focused on the application of multifunctional nano-and-biomaterials for cancer therapy and diagnosis, especially for tumour imaging and targeting, gene therapy/editing and drug delivery.

​

     Our research, conducted at NOVA Medical School and Universidade NOVA de Lisboa, is in line with Sustainable Development Goals (SDG) from United Nations, particularly with Goal 3 of Agenda 2030 to ensure healthy lives and promote well-being for all at all ages, as well as aligned with Goal 9 promoting inclusive and sustainable industrialization and foster innovation.

​